Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Current assets:
Cash and cash equivalents	$ 250,590	$ 406,704
Accounts receivable, net	41,021	23,296
Marketable securities	23,847	27,483
Inventories	30,084	7,584
Prepaid expenses and other current assets	38,047	22,498
Amount due from related party	2,997	580
Total current assets	386,586	488,145
Property and equipment, net	2,546	2,944
Operating lease right-of-use asset	7,098	7,961
Other assets	7,291	20,961
Total assets	403,521	520,011
Current liabilities:
Accounts payable	12,217	12,250
Accrued expenses and other current liabilities	87,333	68,594
Deferred revenue	117,231	100,564
Amounts due to Pfizer	25,768	32,563
Cost share advance from Pfizer	0	33,818
Operating lease liability	2,703	2,148
Amounts due to related parties	501	393
Total current liabilities	245,753	250,330
Deferred revenue, non-current	350,014	375,706
Long-term operating lease liability	5,480	7,041
Long-term debt, less current maturities (related party)	358,700	358,700
Other liabilities	1,717	1,711
Total liabilities	961,664	993,488
Commitments and contingencies (Note 9)
Shareholders’ deficit:
Common shares, par value $0.000017727 per share, 564,111,242 shares authorized, 97,028,258 and 94,858,446 issued and outstanding at December 31, 2022 and March 31, 2022, respectively	2	2
Additional paid-in capital	835,754	795,935
Accumulated other comprehensive loss	(17,285)	(17,285)
Accumulated deficit	(1,376,614)	(1,252,129)
Total shareholders’ deficit	(558,143)	(473,477)
Total liabilities and shareholders’ deficit	$ 403,521	$ 520,011